We represented Lineagen, Inc., a provider of molecular diagnostics services for individuals showing clinical presentations consistent with neurodevelopmental disorders, in its sale to Bionano Genomics, Inc. (Nasdaq: BNGO), a genome analysis company providing tools and services to scientists and clinicians conducting genetic research and patient testing, for $9.6 million.
Lineagen Sells to Bionano Genomics
You Also May Be Interested In:
ALS Education’s Charter School Management Business Sold to Satori Capital, Epic Partners Backed Company
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers